What is it about?
Here we describe the construction and characterization of MTBVAC, the first live attenuated Tuberculosis vaccine constructed from a TB strain from human origin that is in Clinical Trials.
Featured Image
Why is it important?
MTBVAC contains the antigens present in TB strains transmitted by respiratory route that are absents in present vaccine BCG derived from animal origin.
Read the Original
This page is a summary of: Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials, Vaccine, October 2013, Elsevier,
DOI: 10.1016/j.vaccine.2013.07.051.
You can read the full text:
Resources
Contributors
The following have contributed to this page
